Kessler's limits on FDA reform

WASHINGTON - The prospects for congressional action on FDA reform are likely to be clarified by the tone and substance of a hearing this week of the House Commerce Committee's health and the environment subcommittee.

The hearing, which follows two days of Senate hearings last week at which FDA Commissioner David Kessler rejected most of the specific measures contained in Sen. Nancy Kassebaum's FDA reform legislation, is likely to unveil the substance of the House approach to reform...